Glycomimetics Inc financial data

Symbol
GLYC on Nasdaq
Location
9708 Medical Center Drive, Rockville, MD
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 669 % +19.4%
Debt-to-equity 42.6 % +75.6%
Return On Equity -145 % -213%
Return On Assets -90.1 % -171%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.9M shares -78.5%
Common Stock, Shares, Outstanding 13.9M shares -78.5%
Entity Public Float 17.5M USD -84%
Common Stock, Value, Issued 14K USD -78.3%
Weighted Average Number of Shares Outstanding, Basic 64.5M shares +0.1%
Weighted Average Number of Shares Outstanding, Diluted 64.5M shares +1.79%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 31.9M USD +723%
General and Administrative Expense 25.8M USD +3405%
Operating Income (Loss) -65.2M USD -884%
Nonoperating Income (Expense) 1.41M USD +131%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -76M USD -835%
Earnings Per Share, Basic 0 USD/shares +20.7%
Earnings Per Share, Diluted 0 USD/shares -1.72%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 133M USD +826%
Assets, Current 135M USD +760%
Property, Plant and Equipment, Net 782K USD
Operating Lease, Right-of-Use Asset 1.56M USD
Other Assets, Noncurrent 1.25M USD
Assets 138M USD +781%
Accounts Payable, Current 105K USD -86.1%
Employee-related Liabilities, Current 2.75M USD
Accrued Liabilities, Current 8.97M USD +158%
Liabilities, Current 20.3M USD +370%
Operating Lease, Liability, Noncurrent 1.32M USD
Liabilities 21.6M USD +400%
Retained Earnings (Accumulated Deficit) -79.4M USD +83.7%
Stockholders' Equity Attributable to Parent 117M USD
Liabilities and Equity 138M USD +781%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.11M USD +51.4%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 175M shares +16.7%
Common Stock, Shares, Issued 13.9M shares -78.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.11M USD +51.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 133M USD
Deferred Tax Assets, Valuation Allowance 171M USD +5.81%
Deferred Tax Assets, Gross 171M USD +5.67%
Operating Lease, Liability 1.74M USD +564%
Depreciation 0 USD -100%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -24.6M USD -835%
Lessee, Operating Lease, Liability, to be Paid 2.07M USD +675%
Property, Plant and Equipment, Gross 2.64M USD +0.54%
Operating Lease, Liability, Current 417K USD +59.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 608K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 584K USD +766%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 333K USD +5946%
Lessee, Operating Lease, Liability, to be Paid, Year Three 633K USD
Deferred Tax Assets, Operating Loss Carryforwards 96.8M USD +9.09%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 107K USD
Operating Lease, Payments 660K USD -29.3%
Additional Paid in Capital 192M USD -61.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 211K USD -39.8%
Share-based Payment Arrangement, Expense 9.96M USD +2777%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%